Axsome Therapeutics, Inc. announced that the first patient has been dosed in the CLARITY Phase 3 trial evaluating solriamfetol for major depressive disorder with excessive daytime sleepiness symptoms. CLARITY is a double-blind, placebo-controlled, multicenter randomized withdrawal study with an open-label treatment period followed by a randomized phase in which responders continue solriamfetol or switch to placebo; the primary endpoint is time from randomization to relapse of depressive symptoms. No trial results were presented in the announcement; results are expected to be reported in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.